

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/701,500	1	1/29/2000	David A Cheresh	TSRI 651.1	5356	
2387	7590	08/18/2003				
OLSON & HIERL, LTD. 20 NORTH WACKER DRIVE			EXAMINER			
36TH FLOOR				SCHNIZER, RICHARD A		
CHICAGO, IL 60606				ART UNIT	PAPER NUMBER	
				1635	6	
				DATE MAILED: 08/18/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>		Application N		A - 1! 4/				
1		Application No.		Applicant(s)				
	Office Action Summary	09/701,500		CHERESH ET AL.				
	Office Action Summary	Examiner		Art Unit				
	The MAILING DATE - 541:	Richard Schni		1635				
Period fo	The MAILING DATE of this communication apports.  Output  Description:	pears on the cov	er sheet with the c	orrespondence address				
- External control con	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a repl period for reply is specified above, the maximum statutory period re to reply within the set or extended period for reply will, by statute eply received by the Office later than three months after the mailing dipatent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, horey within the statutory me will apply and will expire the application	wever, may a reply be tim ninimum of thirty (30) days e SIX (6) MONTHS from	nely filed s will be considered timely. the mailing of set 20:				
1) 🗌	Responsive to communication(s) filed on 13 i	March 2003 .						
2a)□		is action is non-	final.					
3)□ Dispositi	Since this application is in condition for allows closed in accordance with the practice under on of Claims	ance except for	formal matters, pro	osecution as to the merits is 53 O.G. 213.				
4)	Claim(s) 1-38 is/are pending in the application	1.						
,	4a) Of the above claim(s) is/are withdrawn from consideration.							
	Claim(s) is/are allowed.							
	Claim(s) is/are rejected.							
	_							
8) 🗌	Claim(s) <u>1-38</u> are subject to restriction and/or	election requiren	nent.					
	on Papers	<b>,</b>						
9) 🗌 7	The specification is objected to by the Examine	r.						
10) 🔲 🏾	he drawing(s) filed on is/are: a)□ accep	oted or b)⊡ objec	ted to by the Exan	niner.				
	Applicant may not request that any objection to the	e drawing(s) be he	eld in abeyance. Se	e 37 CFR 1.85(a).				
11) 🔲 T	he proposed drawing correction filed on	is: a)∏ approv	ed b)∏ disapprov	ved by the Examiner.				
	If approved, corrected drawings are required in rep		ction.					
12)∐ Т	he oath or declaration is objected to by the Ex	aminer.						
Priority u	nder 35 U.S.C. §§ 119 and 120							
13) 🗌	Acknowledgment is made of a claim for foreign	priority under 3	5 U.S.C. § 119(a)	-(d) or (f).				
a)[	] All b) ☐ Some * c) ☐ None of:							
,	1. Certified copies of the priority documents	s have been rece	eived.					
:	<ol><li>Certified copies of the priority documents</li></ol>	s have been rece	eived in Applicatio	n No				
;	Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
	cknowledgment is made of a claim for domestic							
a)	☐ The translation of the foreign language proc cknowledgment is made of a claim for domestic	visional applicati	on has been rece	ived.				
Attachment(			- <del>-</del>					
2) Notice 3) Informa	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	4) 5) 6)	Interview Summary ( Notice of Informal Pa Other:	PTO-413) Paper No(s) tent Application (PTO-152)				
S. Patent and Trace TO-326 (Rev.		on Summary	P	art of Paper No. 6				

Application/Control Number: 09/701,500

Art Unit: 1635

## **DETAILED ACTION**

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-4, 12, 13, 14, and 37 drawn to compositions comprising an active Src protein.

Group II, claim(s) 1, 5-14, and 38, drawn to compositions comprising an inactive Src protein.

Group III, claim(s) 1-4,12-16, 33, and 34, drawn to compositions comprising a nucleotide sequence capable of expressing an active Src protein.

Group IV, claim(s) 1, 5-16, 35, and 36, drawn to drawn to compositions comprising a nucleotide sequence capable of expressing an inactive Src protein.

Group V, claims 17-20 and 28-30, drawn to methods of potentiating angiogenesis by administering a composition comprising an active Src protein.

Group VI, claims 17-20, and 28-32 drawn to methods of potentiating angiogenesis by administering a composition comprising a nucleic acid encoding an active Src protein.

Group VII, claims 17 and 21-30, drawn to methods of inhibiting angiogenesis by administering a composition comprising an inactive Src protein.

Group VIII, claims 17 and 21-32 drawn to methods of inhibiting angiogenesis by administering a composition comprising a nucleic acid encoding an inactive Src protein.

Claims 1-14, 17-32 have been assigned to more than one group because each of these claims comprises more than one invention. Applicant is advised that these claims will be examined only to the extent that they are defined by the elected invention.

Application/Control Number: 09/701,500

Art Unit: 1635

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The technical feature that links the independent claims is a composition comprising a Src protein or a nucleic acid encoding a Src protein. However, this technical feature cannot be a special technical feature under PCT Rule 13.2 because it does not constitute a contribution over the prior art. For example, Zang et al (J. Biol. Chem. (1997) 272(20): 13275-13280) teaches an inactive version of SRC with a Y527F mutation, and a nucleic acid expression vector encoding this Src protein. See e.g. sentence bridging pages 13275 and 13276. Because the technical feature linking the independent claims cannot be a special technical feature under PCT Rule 13.2, a lack of unity exists.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner(s) should be directed to Richard Schnizer, whose telephone number is 703-306-5441. The examiner can normally be reached Monday through Friday between the hours of 6:20 AM and 3:50 PM. The examiner is off on alternate Fridays, but is sometimes in the office anyway.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John Leguyader, can be reached at 703-308-0447. The FAX numbers for art unit 1632 are 703-308-4242, and 703-305-3014. Additionally correspondence can

Application/Control Number: 09/701,500

Art Unit: 1635

be transmitted to the following RIGHTFAX numbers: 703-872-9306 for correspondence

before final rejection, and 703-872-9307 for correspondence after final rejection.

Inquiries of a general nature or relating to the status of the application should be

directed to the Patent Analyst Trina Turner whose telephone number is 703-305-3413.

DAVET. NGUYEN PRIMARY EXAMINER Page 4

Richard Schnizer, Ph.D.